Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow ENTX by emailGet an email when ENTX pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about ENTX, unsubscribe in one click. Privacy
📣 What ENTX Says Is Next
first half of 2027 · “Following the previously announced expansion of the Company’s collaboration with OPKO Health (“OPKO”) in February 2026, Entera and OPKO intend to file an Investigational New Drug (IND) application for EB612 in the first half of 2027.”
Company press release, Aug 7, 2026 · SEC filing
first quarter of 2027 · “The Company’s available funds are expected to support operations through the first quarter of 2027, including activities related to the preparation of the planned Phase 3 registrational study of EB613.”
Company press release, May 8, 2026 · SEC filing
by year-end 2026 · “Entera and OPKO have jointly determined that Phase 1 data from the injectable formulation, expected by year-end 2026, will catalyse the initiation of the oral OXM tablet to Phase 1.”
Company press release, Mar 27, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full ENTX picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ENTX and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.